JP2009511599A - 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 - Google Patents
電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 Download PDFInfo
- Publication number
- JP2009511599A JP2009511599A JP2008535728A JP2008535728A JP2009511599A JP 2009511599 A JP2009511599 A JP 2009511599A JP 2008535728 A JP2008535728 A JP 2008535728A JP 2008535728 A JP2008535728 A JP 2008535728A JP 2009511599 A JP2009511599 A JP 2009511599A
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- pain
- aliphatic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C1CC2CC2)C2*1C1CC2C1 Chemical compound CC(C1CC2CC2)C2*1C1CC2C1 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72568605P | 2005-10-12 | 2005-10-12 | |
PCT/US2006/040156 WO2007047474A2 (en) | 2005-10-12 | 2006-10-12 | Biphenyl derivatives as modulators of voltage gated ion channels |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009511599A true JP2009511599A (ja) | 2009-03-19 |
JP2009511599A5 JP2009511599A5 (de) | 2009-11-05 |
Family
ID=37836784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008535728A Pending JP2009511599A (ja) | 2005-10-12 | 2006-10-12 | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 |
Country Status (15)
Country | Link |
---|---|
US (2) | US7683083B2 (de) |
EP (1) | EP1934191B1 (de) |
JP (1) | JP2009511599A (de) |
KR (1) | KR20080059292A (de) |
CN (1) | CN101365690A (de) |
AT (1) | ATE551333T1 (de) |
AU (1) | AU2006304283B2 (de) |
CA (1) | CA2624831A1 (de) |
ES (1) | ES2383090T3 (de) |
IL (1) | IL190632A0 (de) |
NO (1) | NO20082165L (de) |
NZ (1) | NZ567570A (de) |
RU (1) | RU2008118350A (de) |
WO (1) | WO2007047474A2 (de) |
ZA (1) | ZA200803704B (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
MX2007014180A (es) | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
MX2008003337A (es) | 2005-09-09 | 2008-09-26 | Vertex Pharma | Derivados biciclicos como modulares de canales ionicos regulados por voltaje. |
CA2624831A1 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
CA2626190A1 (en) * | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
EP2158183A2 (de) | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ionenkanalmodulatoren und verfahren zur verwendung |
US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
AU2008321137A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
ES2377172T3 (es) * | 2007-11-13 | 2012-03-23 | Vertex Pharmaceuticals Incorporated | Derivados heterocíclicos como moduladores de canales iónicos |
WO2009133641A1 (ja) * | 2008-04-30 | 2009-11-05 | シャープ株式会社 | 照明装置、及び表示装置 |
CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
EP2935257B1 (de) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclische sulfonamide als natriumkanalblocker |
CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
US20200270237A1 (en) * | 2017-10-19 | 2020-08-27 | Esteve Pharmaceuticals, S.A. | New alkoxyamino compounds for treating pain and pain related conditions |
SG11202100137TA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
WO2020163236A1 (en) * | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Treating long qt syndrome |
KR20240035395A (ko) | 2021-06-14 | 2024-03-15 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 사용할 수 있는 요소 유도체 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534336A (ja) * | 2000-05-22 | 2003-11-18 | バイオビトルム アクチボラゲット | 11−ベータ−ヒドロキシステロイド・デヒドロゲナーゼタイプ1の阻害因子 |
JP2005509677A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 1型11−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤 |
JP2005509676A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型のインヒビター |
WO2005060963A1 (en) * | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
JP2007501804A (ja) * | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
CA2624831A1 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
-
2006
- 2006-10-12 CA CA002624831A patent/CA2624831A1/en not_active Abandoned
- 2006-10-12 NZ NZ567570A patent/NZ567570A/en not_active IP Right Cessation
- 2006-10-12 US US11/546,669 patent/US7683083B2/en active Active
- 2006-10-12 RU RU2008118350/04A patent/RU2008118350A/ru not_active Application Discontinuation
- 2006-10-12 WO PCT/US2006/040156 patent/WO2007047474A2/en active Application Filing
- 2006-10-12 ES ES06816908T patent/ES2383090T3/es active Active
- 2006-10-12 KR KR1020087011101A patent/KR20080059292A/ko not_active Application Discontinuation
- 2006-10-12 AU AU2006304283A patent/AU2006304283B2/en not_active Ceased
- 2006-10-12 AT AT06816908T patent/ATE551333T1/de active
- 2006-10-12 JP JP2008535728A patent/JP2009511599A/ja active Pending
- 2006-10-12 EP EP06816908A patent/EP1934191B1/de not_active Not-in-force
- 2006-10-12 CN CNA2006800448581A patent/CN101365690A/zh active Pending
-
2008
- 2008-04-06 IL IL190632A patent/IL190632A0/en unknown
- 2008-04-29 ZA ZA2008/03704A patent/ZA200803704B/en unknown
- 2008-05-13 NO NO20082165A patent/NO20082165L/no not_active Application Discontinuation
-
2010
- 2010-02-01 US US12/697,671 patent/US8236833B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534336A (ja) * | 2000-05-22 | 2003-11-18 | バイオビトルム アクチボラゲット | 11−ベータ−ヒドロキシステロイド・デヒドロゲナーゼタイプ1の阻害因子 |
JP2005509677A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 1型11−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤 |
JP2005509676A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型のインヒビター |
JP2007501804A (ja) * | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
WO2005060963A1 (en) * | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
Also Published As
Publication number | Publication date |
---|---|
CA2624831A1 (en) | 2007-04-26 |
CN101365690A (zh) | 2009-02-11 |
EP1934191B1 (de) | 2012-03-28 |
ATE551333T1 (de) | 2012-04-15 |
EP1934191A2 (de) | 2008-06-25 |
NO20082165L (no) | 2008-07-09 |
US20100130548A1 (en) | 2010-05-27 |
RU2008118350A (ru) | 2009-11-20 |
IL190632A0 (en) | 2008-11-03 |
US20080113990A1 (en) | 2008-05-15 |
US8236833B2 (en) | 2012-08-07 |
NZ567570A (en) | 2011-02-25 |
WO2007047474A2 (en) | 2007-04-26 |
ZA200803704B (en) | 2009-09-30 |
US7683083B2 (en) | 2010-03-23 |
WO2007047474A3 (en) | 2007-07-05 |
AU2006304283A1 (en) | 2007-04-26 |
ES2383090T3 (es) | 2012-06-18 |
AU2006304283B2 (en) | 2012-01-19 |
KR20080059292A (ko) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009511599A (ja) | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 | |
EP1888558B1 (de) | Bicyclische derivate als modulatoren von ionenkanälen | |
US7989481B2 (en) | Indane derivatives as modulators of ion channels | |
US8357702B2 (en) | Bicyclic derivatives as modulators of voltage gated ion channels | |
JP5112297B2 (ja) | イオンチャネルのモジュレーターとして有用なキノリン誘導体 | |
JP2008540539A (ja) | イオンチャンネルの調節因子としての二環系誘導体 | |
JP2010528035A (ja) | イオンチャネル調節物質およびその使用 | |
JP2010539244A (ja) | イオンチャネルのモジュレーターとしてのピリジルスルホンアミド | |
JP2011503191A (ja) | イオンチャネルのモジュレーターとしての複素環誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090911 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121011 |